Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.
Br J Clin Pharmacol. 2013 May;75(5):1312-20. doi: 10.1111/bcp.12006.
Foissac F, Tréluyer JM, Souberbielle JC, Rostane H, Urien S, Viard JP.
EA 3620 Université Paris Descartes, Sorbonne Paris Cité, France. frantz.foissac@cch.aphp.fr
AIMS: Vitamin D deficiency is prevalent in HIV-infected patients and has been associated with osteopenia and HIV disease progression. Our aims were to investigate the pharmacokinetics of 25-hydroxycholecalciferol [25(OH)D], the effect of antiretroviral treatment (ARV) and others factors that may influence the pharmacokinetics, and to determine a vitamin D3 dosing scheme to reach the 30 ng ml(-1) threshold (defined as 25(OH)D sufficiency).
METHODS: This monocentric retrospective study included 422 HIV-infected patients aged 16 to 85 years. A total of 723 25(OH)D concentrations were available for pharmacokinetic evaluation and a population pharmacokinetic model was developed with MONOLIX 3.2.
RESULTS: Median 25(OH)D at baseline was 16 ng ml(-1) (interquartile range 11-23 ng ml(-1)) for the total population, 17% of patient had concentrations below 10 ng ml(-1), 68% between 10 and 30 ng ml(-1) and 15% above 30 ng ml(-1). 25(OH)D pharmacokinetics were best described by a one compartment model with an additional endogenous production. The effects of season and skin phototype were significant on production rate. The endogenous production was 20% lower in non-white skin phototype patients and was decreased by 16% during autumn, winter and spring. No significant differences in 25(OH)D concentrations were related to antiretroviral drugs (ARV). To obtain concentrations between 30 and 80 ng ml(-1), the dosing recommendation was 100,000 IU every month.
CONCLUSIONS: Season and skin phototype had an influence on the endogenous production of 25(OH)D.
However no effect of ARV was found.
A dosing scheme to reach sufficient 25(OH)D concentrations is proposed.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
PMID: 23072545, [PubMed - indexed for MEDLINE]
PMC3635601 [Available on 2014/5/1]
Note by VitaminDWiki
The 100,000 IU vitamin D monthly will most likely get most of patients to > 30ng
Study states that this does not interfer with antiretroviral drug treatment of HIV
It does not speculate or indicate if this is enough to treat HIV.
See also VitaminDWiki
Items in both categories HIV and Intervention are listed here:
- HIV treatment augmented by high-dose vitamin D, daily or weekly – Dec 2021
- HIV therapy reduces Vitamin D levels, supplementation helps - Nov 2019
- HIV patients helped by monthly 120,000 IU of Vitamin D – RCT Oct 2017
- 200,000 IU restored levels in HIV children having low vitamin D - Nov 2014
- Vitamin D levels of HIV and non HIV equally restored with 50,000 IU twice a week - July 2015
- Treatment of HIV in youths helped by 7,000 IU of vitamin D for 1 year – RCT July 2014
- Those with HIV who doubled their vitamin D levels reduced their chance of death by 47 percent – Oct 2013
- HIV – recommend 100,000 IU vitamin D monthly to get levels 30 ng – May 2013